Cannabidiol (Epidiolex)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Study the Efficacy of Epidiolex for Typical Absence Seizures
Conditions
Study the Efficacy of Epidiolex for Typical Absence Seizures
Trial Timeline
Jul 30, 2021 → May 27, 2023
NCT ID
NCT04899050About Cannabidiol (Epidiolex)
Cannabidiol (Epidiolex) is a approved stage product being developed by Jazz Pharmaceuticals for Study the Efficacy of Epidiolex for Typical Absence Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT04899050. Target conditions include Study the Efficacy of Epidiolex for Typical Absence Seizures.
What happened to similar drugs?
3 of 4 similar drugs in Study the Efficacy of Epidiolex for Typical Absence Seizures were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04899050 | Approved | Completed |
Competing Products
20 competing products in Study the Efficacy of Epidiolex for Typical Absence Seizures